Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...
The two-time U.S. Olympic gold medalist gymnast opens up about her skin condition, her fashion dos and don’ts for eczema, and ...
Amlitelimab, an OX40 ligand–targeting therapy that modulates T-cell-mediated inflammation without causing cell depletion, ...
Millions of Brits with eczema are almost twice as likely to suffer agonising eye and bowel conditions, research suggests.
Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being ...
Winters are known to worsen symptoms of eczema due to dropping temperatures.It is believed that around 8 million people in ...
Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...
Corvus Pharma (CRVS) stock surges as the company plans a Phase 2 trial for its lead asset against eczema following ...
Analyzing patient health care notes recorded during millions of medical appointments at GPs and hospitals across England has ...
The cold, dry air of winter brings challenges for those with chronic hand eczema. Chronic hand eczema (CHE), defined as hand ...
Corvus Pharma reports encouraging data for its eczema drug soquelitinib, showing strong skin improvement and no serious ...
Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results